Karnidin (Lercanidipine Hydrochloride)

Lercanidipine Hydrochloride is a calcium channel blocker indicated for the management of hypertension.

• Hypertension: reduces systolic and diastolic blood pressure to target levels.
• Essential hypertension: provides long‑term control of primary high blood pressure.
• High blood pressure: helps prevent cardiovascular complications associated with sustained elevation.

• Lercanidipine Hydrochloride selectively inhibits calcium influx through L‑type calcium channels in vascular smooth muscle. By reducing intracellular calcium, it promotes vasodilation of peripheral arteries, decreasing systemic vascular resistance and consequently lowering arterial blood pressure without significant negative inotropic effects.

Lercanidipine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Headache: mild to moderate intensity, often transient.
• Flushing: warm sensation with reddening of the skin.
• Peripheral edema: swelling of the ankles or lower legs.
• Dizziness: sensation of light‑headedness, especially after standing.
• Tachycardia: increased heart rate without accompanying chest pain.
• Palpitations: awareness of heartbeats.

Serious or Rare Side Effects

• Angioedema: swelling of face, lips, tongue, or throat requiring emergency care.
• Severe hypotension: marked drop in blood pressure leading to fainting.
• Myocardial infarction: rare occurrence of heart attack.
• Hepatic enzyme elevation: abnormal liver function tests.
• Allergic reactions: rash, itching, or anaphylaxis.
• Cardiac arrhythmias: irregular heart rhythms that may need monitoring.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential risks.

• Blood pressure monitoring: check regularly to ensure therapeutic response and avoid overtreatment.
• Hepatic impairment: use with caution in patients with liver dysfunction, adjusting dose if needed.
• Concomitant antihypertensives: assess for additive blood‑pressure lowering effects.
• Discontinuation: avoid abrupt cessation; taper if long‑term therapy is stopped.
• Pregnancy and lactation: safety not established; prescribe only if benefit outweighs risk.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lercanidipine can interact with several drug classes, influencing its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations and risk of hypotension.
• Grapefruit juice: potentiates vasodilatory effect and can cause excessive blood‑pressure drop.
• Simultaneous use with other dihydropyridine calcium channel blockers: may lead to additive cardiovascular effects.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce drug exposure, diminishing antihypertensive effect.

• Diuretics: can enhance orthostatic hypotension; monitor volume status.
• Beta‑blockers: may mask tachycardia; observe heart rate.
• ACE inhibitors or ARBs: increased risk of renal impairment; check renal function.
• NSAIDs: may attenuate antihypertensive response; assess blood pressure regularly.